For the quarter ending 2025-09-30, OBIO made $861,000 in revenue. -$20,799,000 in net income. Net profit margin of -2415.68%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 861,000 | 836,000 | 868,000 | 436,500 |
| Cost of product revenues | 49,000 | 46,000 | 44,000 | 46,000 |
| Research and development | 14,027,000 | 13,853,000 | 13,482,000 | 10,041,500 |
| Selling, general and administrative | 7,098,000 | 6,264,000 | 6,263,000 | 5,899,000 |
| Total expenses | 21,174,000 | 20,163,000 | 19,789,000 | 15,986,500 |
| Loss from operations | -20,313,000 | -19,327,000 | -18,921,000 | -15,550,000 |
| Other expense | - | - | - | -2,750 |
| Interest (expense) income, net | -515,000 | -36,000 | 166,000 | 758,750 |
| Loss on fair value of strategic investments | - | - | - | -15,000 |
| Total other (expense) income | -515,000 | -36,000 | 166,000 | 741,000 |
| Net loss | -20,828,000 | -19,363,000 | -18,755,000 | -14,809,000 |
| Unrealized gain (loss) on marketable securities | 29,000 | -21,000 | -15,000 | -22,000 |
| Comprehensive loss | -20,799,000 | -19,384,000 | -18,770,000 | -14,831,000 |
| Earnings per share, basic | -0.4 | -0.5 | -0.49 | -0.4 |
| Earnings per share, diluted | -0.4 | -0.5 | -0.49 | -0.4 |
| Weighted average number of shares outstanding, basic | 52,186,503 | 38,392,716 | 38,235,409 | -18,300,363 |
| Weighted average number of shares outstanding, diluted | 52,186,503 | 38,392,716 | 38,235,409 | -18,300,363 |
Orchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings, Inc. (OBIO)